HHS weighs interim access for unapproved synthetic peptides

The Department of Health and Human Services is reportedly considering a policy that would permit specialty pharmacies to compound specific synthetic peptides lacking U.S. Food and Drug Administration approval. This interim measure would provide access to certain compounds currently excluded from the standard federal regulatory pathway. Health Secretary Robert F. Kennedy Jr. voiced support for these injectables, calling himself a "big fan" in a February 2026 conversation with podcaster Joe Rogan.

Peptides are chemical compounds composed of short amino acid chains, often described as protein building blocks. While some, such as GLP-1 drugs like Ozempic for weight loss and diabetes, are well-researched and federally approved, many others lack this status. Dr. Pieter Cohen, an associate professor at Harvard Medical School and internist at Cambridge Health Alliance, suggests that the popularity of drugs like Ozempic has likely fueled consumer curiosity about other synthetic peptides, with some hoping these chemical relatives might yield similar benefits in different health areas.

Regulatory concerns remain because several peptides, including BPC-157 which is reportedly part of the health department's proposal, appear on an FDA list of injectables posing significant safety risks. BPC-157 has shown potential anti-inflammatory effects in animal and lab studies but has not undergone large-scale human testing for safety or effectiveness. Dr. Caleb Alexander, a professor of epidemiology and medicine at the Johns Hopkins Bloomberg School of Public Health, points to the lack of robust human studies as a key reason for caution. He notes concerns about both potential risks and the uncertain benefit of these products.

Social media marketing drives consumer interest, with claims ranging from longevity boosts and improved sleep to immune strengthening and sexual function enhancements. Dr. Alison Dempsey, a dermatologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital, observes that word of mouth has significantly outpaced the current state of research in peptide marketing. Injectable synthetic peptides not approved by the FDA, such as BPC-157 and GHK-Cu, are currently generating significant headlines in the wellness market.

Health experts interviewed by CNBC Make It advise against using any injectable peptides without FDA approval, especially when the production source is unknown. Synthetic peptides sold on the so-called gray market are frequently produced by overseas sellers and distributed to U.S. consumers outside normal American drug regulations. Cohen warns that purchasing through these channels can lead to receiving different compounds or doses, with some products potentially contaminated by bacteria or other hazardous materials. He recommends avoiding novel, unstudied injectable peptides due to unknown efficacy and safety. Alexander adds that while the U.S. has a strong regulatory system for prescription drugs, advocates for these products should conduct the necessary studies to determine their true safety and effectiveness.